πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,041 results for β€œAdvanced” Clear

  1. Zelboraf 240 mg film-coated tablets

    Ningbo Cancer Hospital

    Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment

    phase 2 small molecule active

    1 trial

  2. Zelenectide Pevedotin, BT8009

    BICYCLE THERAPEUTICS

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Zentalis

    Zentalis Pharmaceuticals

    Advanced Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  4. Ziftomenib

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 2 small molecule active

    1 trial

  5. [177Lu]-NeoB solution for infusion, AAA503

    Advanced Accelerator Applications

    Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake.

    phase 2 small molecule active

    1 trial

  6. anlotinib +TQB2450 + Oxaliplatin+S-1

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. anlotinib+TQB2450+nab-paclitaxel+cisplatin

    The First People's Hospital of Lianyungang

    Advanced Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  8. anti-IL8 mAb, Ipilimumab, anti-IL8 mAb, 5% dextrose solution for injection, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, 0.9% sodium chloride solution for injection

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  9. bezuclastinib

    Cogent Biosciences

    Advanced Systemic Mastocytosis (AdvSM)

    phase 2 small molecule active

    1 trial

  10. cemiplimab

    Regeneron UK Limited

    Advanced Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  11. cetrelimab, JNJ-63723283

    Janssen-Cilag International N.V.

    Advanced Stage Solid Tumors

    phase 2 small molecule active

    1 trial

  12. chidamide，fulvestrant

    The First People's Hospital of Lianyungang

    Hormone Receptor-positive Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  13. docetaxel, cisplatin, fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Head and Neck Carcinoma

    phase 2 small molecule completed

    1 trial

  14. docetaxol, cisplatin, capecitabine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  15. genexolPM + cisplatin

    Solid Biosciences

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  16. indibulin

    Alaunos Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    2 trials

  17. intravenous infusion (IV) of Adebrelimab (ADE)

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  18. ivosidenib and nivolumab

    Agios Netherlands B.V.

    Advanced Solid Tumor

    phase 2 small molecule completed

    1 trial

  19. linrodostat mesylate; IDO1 inhibitor, linrodostat mesylate; IDO1 inhibitor, Ipilimumab, Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion., linrodostat mesylate; IDO1 inhibitor, Ipilimumab

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  20. lurbinectedin, JEMPERLI 500 mg concentrate for solution for infusion

    The George Institute

    Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy

    phase 2 small molecule active

    1 trial

  21. mFOLFOXIRI

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer

    phase 2 small molecule active

    1 trial

  22. pelareorep, Tecentriq 840 mg concentrate for solution for infusion

    ONCOLYTICS BIOTECH INC

    Patients with advanced or metastatic gastrointestinal (GI) tumors.

    phase 2 small molecule active

    1 trial

  23. pembrolizumab

    The First People's Hospital of Lianyungang

    Advanced Non-squamous Non-small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. rezatapopt

    PMV Pharmaceuticals

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources